|
US2019192428A1
|
|
Oral cannabinoid formulations
|
|
WO2019143925A1
|
|
Liquid rizatriptan compositions
|
|
US2019209494A1
|
|
Methods of stabilizing epinephrine
|
|
CA3086158A1
|
|
Methods of stabilizing dronabinol
|
|
US2019070105A1
|
|
Liquid naloxone spray
|
|
US2019106232A1
|
|
System and method for purging oxygen from medical vials
|
|
US2018289639A1
|
|
Epinephrine spray formulations
|
|
US2018289617A1
|
|
Epinephrine spray formulations
|
|
US2018339842A1
|
|
Actuator for a package and method of use
|
|
WO2018195029A1
|
|
Epinephrine spray formulations
|
|
US2018153795A1
|
|
Liquid buprenorphine formulations
|
|
US2018147143A1
|
|
Liquid naloxone spray
|
|
US2018028489A1
|
|
Stable cannabinoid formulations
|
|
CA3062814A1
|
|
Stable cannabinoid formulations
|
|
CN109922805A
|
|
Liquid naloxone is spraying
|
|
WO2017205710A1
|
|
Sublingual fentanyl formulations containing a permeation enhancer
|
|
US2017340620A1
|
|
Sublingual opioid formulations containing naloxone
|
|
US2017252337A1
|
|
Liquid naloxone spray
|
|
US2017224634A1
|
|
Stable cannabinoid formulations
|
|
WO2017204986A1
|
|
Stable cannabinoid formulations
|
